Managing superficial pyoderma with light therapy - DVM 360

Phovia is highly effective for treating superficial and deep skin infections.

This article is sponsored by Vetoquinol.

Superficial bacterial folliculitis, also called superficial pyoderma, is a commonly diagnosed dermatological condition in dogs.^1,2 These infections are secondary to primary conditions affecting normal skin barrier function (eg, allergic skin disease, trauma, burns), keratinization (eg, nutritional deficiency, liver disease), and immune regulation (eg, neoplasia, autoimmunity, endocrinopathy).² Cats less commonly develop superficial pyoderma perhaps because of decreased adhesion of staphylococci to feline corneocytes, but the primary issues causing infection are similar to those seen in dogs.^3-8

The primary pathogen associated with superficial pyoderma in dogs and cats is a normal resident of the skin, Staphylococcus pseudintermedius, but other flora may be involved.^2,8-12 As the normal homeostasis of this organism is disrupted from a primary disease, these gram-positive cocci invade deeper regions of the epidermis and hair follicle epithelium, increase in number, and enhance inflammation.

Classical clinical lesions of superficial pyoderma include papules and pustules that may eventually progress to alopecia, epidermal collarettes, scales, and crusts. Often the skin is erythematous and pruritic. Chronic cases may demonstrate lichenification, hyperpigmentation, and scarring alopecia from long-standing inflammation and infection.² Cats may develop even more unique cutaneous reaction patterns and skin lesions—especially when allergic skin disease is present—including miliary dermatitis, eosinophilic plaques, rodent ulcers, and eosinophilic granulomas.⁵

Identifying and addressing the primary disease is paramount in achieving complete, permanent resolution of the superficial pyoderma. Therefore, treatment is multifactorial and aimed at addressing the primary disease, reducing skin inflammation, and treating the infection directly. Current guidelines for the treatment of superficial pyoderma in dogs recommend the use of topical antimicrobials as sole therapy whenever possible; however, overuse of systemic antibiotics remains common.^2,13-16

Topical therapy has many benefits including direct antimicrobial effects without use of an antibiotic, reduction in antibiotic-resistant bacterial populations, restoration of the normal skin barrier, enhancement of skin hydration, physical removal of keratinous debris, and removal of offending allergens from the haircoat.^2,14 However, topical therapy is met with challenges that impede clinical application. Adherence is the biggest concern when recommending topical therapy to pet owners. Frequent bathing or application of medicated solutions to the skin can be difficult when busy owner lifestyles combine with a nonadherent patient. Skin inflammation can be painful and animals may be resistant to topical therapy. Cats are fastidious groomers and may lick away a medicated topical therapy before it can achieve appropriate contact time. Additionally, some topical agents can cause oral erosions and ulcerations or even gastrointestinal disturbance when groomed off. For these reasons, systemic antibiotics continue to be a common prescribing practice for superficial pyoderma.

All antibiotic use, despite duration or frequency, contributes to the development of antibiotic-resistant bacterial populations on the animal and in the environment.^17-19 From that very first dose, bacteria are constantly evolving to implement inherent and acquired resistance mechanisms necessary for survival. One well-recognized mechanism is oxacillin resistance through the mecA gene, which produces a penicillin-binding protein receptor with poor affinity for β-lactam antibiotics.^{2,14,15,20-23} Even more concerning than these oxacillin-resistant strains are those that develop multidrug resistance, which is defined as resistance to 3 or more antibiotic drug classes. This may happen over time with repeated antibiotic exposure or after a single dose of certain antibiotics such as fluorinated quinolones.^2,20,23-25 The continued emergence of antibiotic-resistant bacteria inhibits the successful treatment of bacterial infections in pets and humans. As veterinarians consider how their antibiotic use contributes to this growing pandemic, they must look for alternative, safe, effective, affordable, and convenient antibacterial treatment modalities.

Phovia as a solution

Investigation into the photobiological effects of light therapy has been ongoing for the past 50 years. Photobiomodulation (PBM) therapy is a type of light treatment that uses visible or near infrared light to promote therapeutic benefits including induction of tissue healing and regeneration and inhibition of biological responses that induce pain or inflammation. The treatment distance, wavelength, fluence, pulse parameters, spot size, and irradiation time influence the effects of light energy on tissue. Visible light with wavelengths ranging from 400 to 700 nm can stimulate positive photobiomodulatory effects that promote wound healing, reduce inflammation and pain, modulate stem cell populations, and reduce bacterial contamination of wounds.^26,27

Once visible light enters the skin, it is absorbed by the cells and initiates chemical changes dependent on the wavelength (or color) of light and the chromophore within the skin.²⁷ Within each cell, membrane-bound organelles called mitochondria contain chromophores that absorb the light energy and begin making energy (adenosine triphosphate; ATP) via activation of cytochrome c oxidase. Outcomes of the mitochondrial respiratory pathway activation include stimulation of secondary messenger pathways, production of transcription factors and growth factors, and increased ATP production. However, excessive light energy exposure will overstimulate mitochondrial respiration and cause expenditure of all ATP reserves, which creates oxidative stress resulting in damaging elevations of nitric oxide, production of harmful free radicals, and activation of cytotoxic mitochondrial-signaling pathways leading to apoptosis.^27,28 This is why creating PBM therapy protocols is important for targeting the beneficial effects while avoiding unintended harm.

Specific benefits of light energy within the visible light spectrum can be broken down into each color of light. Blue light (400-500 nm) has a lower penetration depth and primarily interacts with keratinocytes, reduces bacterial adhesion and growth, and increases intracellular calcium and osteoblast differentiation.^29-31 Green light (495-570 nm) affects the superficial tissue and alters melanogenesis, reduces hyperpigmentation of the skin, and reduces tissue swelling.^29,30 Red light (600-750 nm) penetrates deeper into the dermis and subcutis where it acts on cellular mitochondria to reduce inflammation and promote collagen synthesis through fibroblast proliferation and production of transforming growth factor-β, fibroblast growth factor, platelet derived growth factor, and others.^26-28,32,33 Red light has proliferative effects on mesenchymal stem cells and induces proliferation of epithelial colony forming units important for tissue repair and regeneration.^34,35

Phovia, sold by Vetoquinol, is a form of fluorescent PBM therapy utilizing a blue light emitting diode (LED lamp, 400-460 nm) and topical photoconverter gel that emits low-energy fluorescent light (510-600 nm) when illuminated by the LED lamp.^36,37 This interaction results in the formation of multiple wavelengths of visible light, each with a unique depth of penetration and effect on the tissue as described above. Application is fast and simple. The affected skin may be clipped free of hair and cellular debris removed with gentle cleaning. The skin is allowed to dry before application of the photoconverter gel. Just prior to application, 1 ampule of fluorescence chromophore gel is added to 1 container of photoconverter carrier gel and mixed thoroughly. The mixture is applied in a 2-mm layer to the affected skin, and the LED lamp is held 5 cm above the lesion and used to illuminate the area for 2 minutes. The gel is wiped away using saline-soaked gauze. The application can be repeated immediately after 5 to 10 minutes of rest or a second application can occur a few days later. Twice-weekly applications are continued until the wound is healed. Appropriate eyewear is required to protect the operator from the intensely bright light. Application is pain free and stress free for the patient, so sedation is not typically required.

Benefits of Phovia

Phovia shows great promise as a safe, effective therapy for treatment of numerous inflammatory dermatoses in dogs including superficial pyoderma,³⁸ deep pyoderma,³⁹ perianal fistula,⁴⁰ interdigital dermatitis,⁴¹ calcinosis cutis,⁴² acute traumatic wounds,⁴³ chronic wounds,³⁷ surgical wounds,⁴⁴ and otitis externa.⁴⁵ Phovia as a sole therapy speeds time to healing by 36% in canine superficial pyoderma as compared with dogs receiving oral antibiotics alone.³⁸ In one study, dogs with superficial pyoderma were treated with Phovia alone or with an oral antibiotic alone. Dogs treated twice weekly with Phovia demonstrated complete clinical healing in about 2.3 weeks (P < .05)whereas dogs receiving oral antibiotic healed in about 3.75 weeks.³⁸ Additionally, Phovia speeds time to healing by nearly 50% in deep pyoderma when used with an oral antibiotic (5.7 weeks of treatment) compared with dogs receiving only oral antibiotic (11.7 weeks of treatment).³⁹ The ability of this fluorescent PBM therapy to eliminate or significantly reduce duration of exposure to antibiotics will decrease the spread of antibiotic-resistant bacterial strains within pets and humans.

Phovia's high safety profile makes it a beneficial tool to implement in everyday practice. Training the veterinary team to communicate therapy benefits with clients as well as to perform treatments is fast and easy. Training the veterinary technicians to perform treatments will give the veterinarian time to examine other patients. A single back-to-back application takes about 15 minutes, so pet owners can be in and out of the clinic quickly; however, the 2 weekly treatments can be separated by a few days if the veterinarian prefers to evaluate the patient more frequently. Additionally, when used as a sole therapy, clients are not required to administer oral or topical medications at home. This greatly improves treatment adherence and success. Instruct clients to use once-daily smartphone photos to document improvement at home. This can be useful when deciding how many treatments to perform. Most cases of superficial pyoderma will resolve completely by the third treatment.³⁸ It is a good idea to communicate to clients that 3 to 4 weekly treatments may be required.

Conclusion

Phovia is a versatile, innovative therapeutic approach to numerous types of dermatitis.³⁶ It is easy to implement in general practice, and is safe, pain free, and affordable. Phovia is highly effective for superficial and deep skin infections and eliminates the need for clients to administer numerous at-home treatments. This greatly improves the pet-owner bond and treatment outcomes by promoting adherence. Phovia accelerates time to wound healing, which decreases duration of antibiotic exposure and may reduce risk of antibiotic resistance development in these cases.^2,13,36-39 Phovia's efficacy against antibiotic-susceptible and antibiotic-resistant bacteria shows promise as an alternative therapeutic approach that promotes the principles of antimicrobial stewardship.³⁶ If you are interested in purchasing this medical device for your practice, contact your Vetoquinol service representative.

Amelia G. White, DVM, MS, DACVD is an associate clinical professor of dermatology at Auburn University College of Veterinary Medicine.

REFERENCES

1. Hill PB, Lo A, Eden CAN, et al. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Vet Rec. 2006;158(16):533-539. doi:10.1136/vr.158.16.533
2. Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol. 2014;25(3):163-e43. doi:10.1111/vde.12118
3. Diesel A. Cutaneous hypersensitivity dermatoses in the feline patient: a review of allergic skin disease in cats. Vet Sci. 2017;4(2):25. doi:10.3390/vetsci4020025
4. Halliwell R, Pucheu-Haston CM, Olivry T, et al. Feline allergic diseases: introduction and proposed nomenclature. Vet Dermatol. 2021;32(1):8-e2. doi: 10.1111/vde.12899
5. Santoro D, Pucheu-Haston CM, Prost C, Mueller RS, Jackson H. Clinical signs and diagnosis of feline atopic syndrome: detailed guidelines for a correct diagnosis. Vet Dermatol. 2021;32(1):26-e6. doi: 10/1111/vde.12935
6. Ravens PA, Xu BJ, Vogelnest LJ. Feline atopic dermatitis: a retrospective study of 45 cases (2001-2012). Vet Dermatol. 2014;25(2):95-102, e27-e28. doi: 10.1111/vde.12109
7. Woolley KL, Kelly RF, Fazakerley J, Williams NJ, Nuttall TJ, McEwan NA. Reduced in vitro adherence of Staphylococcus species to feline corneocytes compared to canine and human corneocytes. Vet Dermatol. 2008;19(1):1-6. doi: 10.1111/j.1365-3164.2007.00649.x
8. Yu HW, Vogelnest LJ. Feline superficial pyoderma: a retrospective study of 52 cases (2001-2011). Vet Dermatol. 2012;23(5):448-e86. doi:10.1111/j.1365-3164.2012.01085.x
9. Nocera FP, Ambrosio M, Fiorito F, Cortese L, De Martino L. On gram-positive- and gram-negative-bacteria-associated canine and feline skin infections: a 4-year retrospective study of the University Veterinary Microbiology Diagnostic Laboratory of Naples, Italy. Animals (Basel). 2021;11(6):1603. doi: 10.3390/ani11061603
10. Medleau L, Blue JL. Frequency and antimicrobial susceptibility of Staphylococcus spp isolated from feline skin lesions. J Am Vet Med Assoc. 1988;193(9):1080-1081.
11. Chermprapai S, Ederveen THA, Broere F, et al. The bacterial and fungal microbiome of the skin of healthy dogs and dogs with atopic dermatitis and the impact of topical antimicrobial therapy, an exploratory study. Vet Microbiol. 2019;229:90-99. doi: 10.1016/j.vetmic.2018.12.022
12. Weese JS. The canine and feline skin microbiome in health and disease. Vet Dermatol. 2013;24(1):137-145.e31. doi: 10.1111/j.1365-3164.2021.01076.x
13. Divala TH, Corbett EL, Stagg HR, et al. Effect of the duration of antimicrobial exposure on the development of antimicrobial resistance (AMR) for macrolide antibiotics: protocol for a systematic review with a network meta-analysis. Syst Rev. 2018;7(1):246. doi: 10.1186/s13643-018-0917-0
14. Morris DO, Loeffler A, Davis MF, Guardabassi L, Weese JS. Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Vet Dermatol. 2017;28(3):304-e69. doi: 10.1111/vde.12444
15. Palma E, Tilocca B, Roncada P. Antimicrobial resistance in veterinary medicine: an overview. Int J Mol Sci. 2020;21(6):1914. doi: 10.3390/ijms21061914
16. Summers JF, Hendricks A, Brodbelt DC. Prescribing practices of primary-care veterinary practitioners in dogs diagnosed with bacterial pyoderma. BMC Vet Res. 2014;10:240. doi: 10.1186/s12917-014-0240-5
17. Lloyd DH. Reservoirs of antimicrobial resistance in pet animals. Clin Infect Dis. 2007;45(suppl 2):S148-S152. doi: 10.1086/519254
18. Pomba C, Rantala M, Greko C, et al. Public health risk of antimicrobial resistance transfer from companion animals. J Antimicrob Chemother. 2017;72(4):957-968. doi: 10.1093/jac/dkw481
19. Zur G, Gurevich B, Elad D. Prior antimicrobial use as a risk factor for resistance in selected Staphylococcus pseudintermedius isolates from the skin and ears of dogs. Vet Dermatol. 2016;27(6):468-e125. doi: 10.1111.vde.12382
20. Descloux S, Rossano A, Perreten V. Characterization of new staphylococcal cassette chromosome mec (SCCmec) and topoisomerase genes in fluoroquinolone- and methicillin-resistant Staphylococcus pseudintermedius. J Clin Microbiol. 2008;46(5):1818-1823. doi: 10.1128/JCM.02255-07
21. Krapf M, Muller E, Reissig A, et al. Molecular characterisation of methicillin-resistant Staphylococcus pseudintermedius from dogs and the description of their SCCmec elements. Vet Microbiol. 2019;233:196-203. doi: 10.1016/j.vetmic.2019.04.002
22. van Duijkeren E, Catry B, Greko C, et al; Scientific Advisory Group on Antimicrobials (SAGAM). Review on methicillin-resistant Staphylococcus pseudintermedius. J Antimicrob Chemother. 2011;66(12):2705-2714. doi: 10.1093/jac/dkr367
23. Yoo JH, Yoon JW, Lee SY, Park HM. High prevalence of fluoroquinolone- and methicillin-resistant Staphylococcus pseudintermedius isolates from canine pyoderma and otitis externa in veterinary teaching hospital. J Microbiol Biotechnol. 2010;20(4):798-802.
24. Hassanzadeh S, Ganjloo S, Pourmand MR, Mashhadi R, Ghazvini K. Epidemiology of efflux pumps genes mediating resistance among Staphylococcus aureus; a systematic review. Microb Pathog. 2020;139:103850. doi: 10.1016/j.micpath.2019.103850
25. Ihrke PJ, Papich MG, DeManuelle TC. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol. 1999;10:193-204.
26. Wang ZX, Kim SH. Effect of photobiomodulation therapy (660 nm) on wound healing of rat skin infected by Staphylococcus. Photobiomodul Photomed Laser Surg. 2020;38(7):419-424. doi: 10.1089/photob.2019.4754
27. Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008;84(2):450-462. doi: 10.1111/j.1751-1097.2007.00286.x
28. Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. J Biomed Opt. 2018;23(12):1-17. doi: 10.1117/1.JBO.23.12.120901
29. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Photobiomodulation (blue and green light) encourages osteoblastic-differentiation of human adipose-derived stem cells: role of intracellular calcium and light-gated ion channels. Sci Rep. 2016;6:33719. doi: 10.1038/srep33719
30. Serrage H, Heiskanen V, Palin WM, et al. Under the spotlight: mechanisms of photobiomodulation concentrating on blue and green light. Photochem Photobiol. 2019;18(8):1877-1909. doi: 10.1039/c9pp00089e
31. de Sousa NTA, Santos MF, Gomes RC, Brandino HE, Martinez R, de Jesus Guirro RR. Blue laser inhibits bacterial growth of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Photomed Laser Surg. 2015;33(5):278-282. doi: 10.1089/pho.2014.3854
32. Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Red (660 nm) or near-infrared (810 nm) photobiomodulation stimulates, while blue (415 nm), green (540 nm) light inhibits proliferation in human adipose-derived stem cells. Sci Rep. 2017;7(1):7781. doi: 10.1038/s41598-017-07525-w
33. Fekrazad R, Sarrafzadeh A, Kalhori KAM, Khan I, Arany PR, Giubellino A. Improved wound remodeling correlates with modulated TGF-beta expression in skin diabetic wounds following combined red and infrared photobiomodulation treatments. Photochem Photobiol. 2018;94(4):775-779. doi: 10.1111/php.12914
34. Fekrazad R, Asefi S, Allahdadi M, Kalhori KAM. Effect of photobiomodulation on mesenchymal stem cells. Photomed Laser Surg. 2016;34(11):533-542. doi: 10.1089/pho.2015.4029
35. Khan I, Arany PR. Photobiomodulation therapy promotes expansion of epithelial colony forming units. Photomed Laser Surg. 2016;34(11):550-555. doi: 10.1089/pho.2015.4054
36. Marchegiani A, Spaterna A, Cerquetella M. Current applications and future perspectives of fluorescence light energy biomodulation in veterinary medicine. Vet Sci. 2021;8(2):20. doi: 10.3390/vetsci8020020
37. Scapagnini G, Marchegiani A, Rossi G, et al. Management of all three phases of wound healing through the induction of fluorescence biomodulation using fluorescence light energy. SPIE Proceedings Volume 10863, Photonic Diagnosis and Treatment of Infections and Inflammatory Diseases II; 108630W (2019).
38. Marchegiani A, Fruganti A, Cerquetella M, Tambella AM, Laus F, Spaterna A. Klox fluorescence biomodulation system (KFBS), an alternative approach for the treatment of superficial pyoderma in dogs: preliminary results. BSAVA Conference Proceedings 2018. 2018:442.
39. Marchegiani A, Fruganti A, Spaterna A, Cerquetella M, Tambella AM, Paterson S. The effectiveness of fluorescent light energy as adjunct therapy in canine deep pyoderma: a randomized clinical trial. Vet Med Int. 2021;2021:6643416. doi: 10.1155/2021/6643416
40. Marchegiani A, Tambella AM, Fruganti A, Spaterna A, Cerquetella M, Paterson S. Management of canine perianal fistula with fluorescence light energy: preliminary findings. Vet Dermatol. 2020;31(6):460-e122. doi: 10.1111/vde.12890
41. Marchegiani A, Spaterna A, Cerquetella M, Tambella AM, Fruganti A, Paterson S. Fluorescence biomodulation in the management of canine interdigital pyoderma cases: a prospective, single-blinded, randomized and controlled clinical study. Vet Dermatol. 2019;30(5):371-e109. doi: 10.1111/vde.12785
42. Apostolopoulos N, Mayer U. Use of fluorescent light energy for the management of bacterial skin infection associated with canine calcinosis cutis lesions. Vet Rec Case Rep. 2020;8(4). doi.org/10.1136/vetreccr-2020-0001285
43. Marchegiani A, Spaterna A, Piccionello AP, Meligrana M, Fruganti A, Tambella AM. Fluorescence biomodulation in the management of acute traumatic wounds in two aged dogs. Vet Med (Praha). 2020;65:215-220. doi.org/10.17221/131/2019-VETMED
44. Salvaggio A, Magi GE, Rossi G, et al. Effect of the topical Klox fluorescence biomodulation system on the healing of canine surgical wounds. Vet Surg. 2020;49(4):719-727. doi: 10.1111/vsu.13415
45. Tambella AM, Attili AR, Beribe F, et al. Management of otitis externa with an led-illuminated gel: a randomized controlled clinical trial in dogs. BMC Vet Res. 2020;16(1):91. doi: 10.1186/s12917-020-02311-9